Podcasts about gynecologic cancers

In this powerful episode of the GOSH Podcast

Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics: Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00) Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38) CME information and select publications

Clinical investigators discuss available data guiding the management of gynecologic cancers.  CME information and select publications here.

In this episode of the GOSH Podcast, host Carly returns to speak with Ashley Greer, a resilient cervical cancer survivor and passionate advocate. Diagnosed in late 2023, Ashley shares her powerful story of navigating treatment—including chemotherapy, radiation, and multiple surgeries—and how she found strength and purpose through it all. Now cancer-free, Ashley is on a mission to raise awareness about early detection and inspire others with her experience of life after cancer. Tune in for an honest, moving, and empowering conversation. Resources:Ashley's Instagram: @ashleys.pathCarly's Instagram: @ostomate_and_the_cityFor more information on the Gynecologic Cancer Initiative, please visit https://gynecancerinitiative.ca/ or email us at info@gynecancerinitiative.ca Where to learn more about us: Twitter – @GCI_Cluster Instagram – @gynecancerinitiative Facebook – facebook.com/gynecancerinitiativeTikTok – @gci_gosh

Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient's perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx. “[Providers] giving me the information and allowing us to decide together, instead of just telling me, makes me feel more cared about and that I'm not just a number, I'm a person. They care about what I think, and look at my life and what it can do for me.” – Nancy Mallett   Nancy Mallett Patient Advocate   Resources:  FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer - https://bit.ly/4is00nD  Society of Gynecologic Oncology (SGO): Gynecologic Cancer Resources for Patients and Their Families - https://bit.ly/4jpYaoP  ASCO: Antibody-Drug Conjugates in Gynecologic Cancer - https://bit.ly/42GP5k8  Society of Gynecologic Oncology Journal Club: The ABCs of ADCs (Antibody drug Conjugates) - https://bit.ly/42U2962  Antibody-Drug Conjugates in Gynecologic Cancers - https://bit.ly/4cLYECZ    Funder Statement  This program is supported by AbbVie.   

Featuring perspectives from Dr Kathleen N Moore, Dr David M O'Malley and Dr Alessandro D Santin, moderated by Dr O'Malley, including the following topics: Introduction (0:00) Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Santin (2:17) Available Data with and Practical Application of HER2-Targeted Therapy for Advanced Gynecologic Cancers — Dr O'Malley (30:24) Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr Moore (1:01:53) CME information and select publications

Drs Kathleen N Moore and Alessandro D Santin and moderator Dr David M O'Malley summarize and share their perspectives on data guiding the management of HER2-positive gynecologic cancers that were presented at the Society of Gynecologic Oncology 2025 annual meeting. CME information and select publications here.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

In this episode of the GOSH Podcast, we continue our rare cancer series with Carly Allen, a passionate advocate and survivor.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MutationalTestinginmCRcMethodsandDataDrivingTreatmentSelection/32942/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/CaseConsultAdverseEffectMonitoringManagementandMitigationDuringTargetedTherapyforBRAFMutantmCRc/33134/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

Dr. Ebony Hoskins and Dr. Andreas Obermair discuss the surgical management of gynecologic cancers, including the role of minimally invasive surgery, approaches in fertility preservation, and the nuances of surgical debulking. TRANSCRIPT Dr. Ebony Hoskins: Hello and welcome to the ASCO Daily News Podcast, I'm Dr. Ebony Hoskins. I'm a gynecologic oncologist at MedStar Washington Hospital Center in Washington, DC, and your guest host of the ASCO Daily News Podcast. Today we'll be discussing the surgical management of gynecologic cancer, including the role of minimally invasive surgery (MIS), approaches in fertility preservation, and the nuances of surgical debulking, timing, and its impact on outcomes. I am delighted to welcome Dr. Andreas Obermair for today's discussion. Dr. Obermair is an internationally renowned gynecologic oncologist, a professor of gynecologic oncology at the University of Queensland, and the head of the Queensland Center for Gynecologic Cancer Research. Our full disclosures are available in the transcript of this episode. Dr. Obermair, it's great speaking with you today. Dr. Andreas Obermair: Thank you so much for inviting me to this podcast. Dr. Ebony Hoskins: I am very excited.  I looked at your paper and I thought, gosh, is everything surgical? This is everything that I deal with daily in terms of cancer in counseling patients. What prompted this review regarding GYN cancer management? Dr. Andreas Obermair: Yes, our article was published in the ASCO Educational Book; it is volume 44 in 2024. And this article covers some key aspects of targeted precision surgical management principles in endometrial cancer, cervical cancer, and ovarian cancer. While surgery is considered the cornerstone of gynecologic cancer treatment, sometimes research doesn't necessarily reflect that. And so I think ASCO asked us to; so it was not just me, there was a team of colleagues from different parts of the United States and Australia to reflect on surgical aspects of gynecologic cancer care and I feel super passionate about that because I do believe that surgery has a lot to offer. Surgical interventions need to be defined and overall, I see the research that I'm doing as part of my daily job to go towards precision surgery. And I think that is, well, that is something that I'm increasingly passionate for. Dr. Ebony Hoskins: Well, I think we should get into it. One thing that comes to mind is the innovation of minimally invasive surgery in endometrial cancer. I always reflect on when I started my fellowship, I guess it's been about 15 years ago, all of our endometrial cancer patients had a midline vertical incision, increased risk of abscess, infections and a long hospital stay. Do you mind commenting on how you see management of endometrial cancer today? Dr. Andreas Obermair: Thank you very much for giving the historical perspective because the generation of gynecologic oncologists today, they may not even know what we dealt with, what problems we had to solve. So like you, when I was a fellow in gynecologic oncology, we did midline or lower crosswise incisions, the length of stay was, five days, seven days, but we had patients in hospital because of complications for 28 days. We took them back to the operating theaters because those are patients with a BMI of 40 plus, 45, 50 and so forth. So we really needed to solve problems. And then I was exposed to a mentor who taught minimal invasive surgery. And in Australia he was one of the first ones who embarked on that. And I can remember, I was mesmerized by this operation, like not only how logical this procedure was, but also we did rounds afterwards. And I saw these women after surgery and I saw them sitting upright, lipstick on, having had a full meal at the end of the day. And I thought, wow, this is the most rewarding experience that I have to round these patients after surgery. And so I was thinking, how could I help to establish this operation as standard? Like a standard that other people would accept this is better. And so I thought we needed to do a trial on this. And then it took a long time. It took a long time to get the support for the [LACE - Laparoscopic Approach to Cancer of the Endometrium] trial. And in this context, I just also wanted to remind us all that there were concerns about minimal invasive surgery in endometrial cancer at the time. So for example, one of the concerns was when I submitted my grant funding applications, people said, “Well, even if we fund you, wouldn't be able to do this trial because there are actually no surgeons who actually do minimally invasive surgery.” And at the time, for example, in Australia, there were maybe five people, a handful of people who were able to do this operation, right? This was about 20 years ago. The other concern people had was they were saying, could minimally invasive surgery for endometrial cancer, could that cause port side metastasis because there were case reports. So there were a lot of things that we didn't know anyway. We did this trial and I'm super happy we did this trial. We started in 2005, and it took five years to enroll. At the same time, GOG LAP2 was ramping up and the LACE trial and GOG LAP2 then got published and provided the foundations for minimally invasive surgery in endometrial cancer. I'm super happy that we have randomized data about that because now when we go back and now when people have concerns about this, should we do minimally invasive surgery in P53 mutant tumors, I'm saying, well, we actually have data on that. We could go back, we could actually do more research on that if we wanted to, but our treatment recommendations are standing on solid feet. Dr. Ebony Hoskins: Well, my patients are thankful. I see patients all the time and they have high risk and morbidly obese, lots of medical issues and actually I send them home most the same day. And I think, you know, I'm very appreciative of that research, because we obviously practice evidence-based and it's certainly a game changer. Let's go along the lines of MIS and cervical cancer. And this is going back to the LACC [Laparoscopic Approach to Cervical Cancer] trial.  I remember, again, one of these early adopters of use of robotic surgery and laparoscopic surgery for radical hysterectomy and thought it was so cool. You know, we can see all the anatomy well and then have the data to show that we actually had a decreased survival. And I even see that most recent updated data just showing it still continued. Can you talk a little bit about why you think there is a difference? I know there's ongoing trials, but still interested in kind of why do you think there's a survival difference? Dr. Andreas Obermair:  So Ebony, I hope you don't mind me going back a step. So the LACC study was developed from the LACE trial. So we thought we wanted to reproduce the LACE data/LAP2 data. We wanted to reproduce that in cervix cancer. And people were saying, why do you do that? Like, why would that be different in any way? We recognize that minimally invasive radical hysterectomy is not a standard. We're not going to enroll patients in a randomized trial where we open and do a laparotomy on half the patients. So I think the lesson that really needs to be learned here is that any surgical intervention that we do, we should put on good evidence footing because otherwise we're really running the risk of jeopardizing patients' outcomes. So, that was number one and LACC started two years after LACE started. So LACC started in 2007, and I just wanted to acknowledge the LACC principal investigator, Dr. Pedro Ramirez, who at the time worked at MD Anderson. And we incidentally realized that we had a common interest. The findings came totally unexpected and came as an utter shock to both of us. We did not expect this. We expected to see very similar disease-free and overall survival data as we saw in the endometrial cancer cohort. Now LACC was not designed to check why there was a difference in disease-free survival. So this is very important to understand. We did not expect it. Like, so there was no point checking why that is the case. My personal idea, and I think it is fair enough if we share personal ideas, and this is not even a hypothesis I want to say, this is just a personal idea is that in endometrial cancer, we're dealing with a tumor where most of the time the cancer is surrounded by a myometrial shell. And most of the time the cancer would not get into outside contact with the peritoneal cavity. Whereas in cervix cancer, this is very different because in cervix cancer, we need to manipulate the cervix and the tumor is right at the outside there. So I personally don't use a uterine manipulator. I believe in the United States, uterine manipulators are used all the time. My experience is not in this area, so I can't comment on that. But I would think that the manipulation of the cervix and the contact of the cervix to the free peritoneal cavity could be one of the reasons. But again, this is simply a personal opinion. Dr. Ebony Hoskins: Well, I appreciate it. Dr. Andreas Obermair: Ebony at the end of the day, right, medicine is empirical science, and empirical science means that we just make observations, we make observations, we measure them, and we pass them on. And we made an observation. And, and while we're saying that, and yes, you're absolutely right, the final [LACC] reports were published in JCO recently. And I'm very grateful to the JCO editorial team that they accepted the paper, and they communicated the results because this is obviously very important. At the same time, I would like to say that there are now three or four RCTs that challenge the LACC data. These RCTs are ongoing, and a lot of people will be looking forward to having these results available. Dr. Ebony Hoskins: Very good. In early-stage cervical cancer, the SHAPE trial looked at simple versus radical hysterectomy in low-risk cervical cancer patients. And as well all know, simple hysterectomy was not inferior to radical hysterectomy with respect to the pelvic recurrence rate and any complications related to surgery such as urinary incontinence and retention. My question for you is have you changed your practice in early-stage cervical cancer, say a patient with stage 1B1 adenocarcinoma with a positive margin on conization, would you still offer this patient a radical hysterectomy or would you consider a simple hysterectomy? Dr. Andreas Obermair:  I think this is a very important topic, right? Because I think the challenge of SHAPE is to understand the inclusion criteria. That's the main challenge. And most people simplify it to 2 cm, which is one of the inclusion criteria but there are two others and that includes the depth of invasion. Dr. Marie Plante has been very clear. Marie Plante is the first author of the SHAPE trial that's been published in the New England Journal of Medicine only recently and Marie has been very clear upfront that we need to consider all three inclusion criteria and only then the inclusion criteria of SHAPE apply. So at the end of the day, I think what the SHAPE trial is telling us that small tumors that would strictly fulfill the criteria of a 1B or 1B1 cancer of the cervix can be considered for a standard type 1 or PIVA type 1 or whatever classification we're trying to use will be eligible. And that makes a lot of sense. I personally not only look at the size, I also look at the location of the tumor. I would be very keen that I avoid going through tumor tissue because for example, if you have a tumor that is, you know, located very much in one corner of the cervix and then you do a standard hysterectomy and then you have a positive tumor margin that would be obviously, most people would agree it would be an unwanted outcome. So I'd be very keen checking the location, the size of the tumor, the depths of invasion and maybe then if the tumor for example is on one side of the cervix you can do a standard approach on the contralateral side but maybe do a little bit more of a margin, a parametrial margin on the other side. Or if a tumor is maybe on the posterior cervical lip, then you don't need to worry so much about the anterior cervical margin, maybe take the rectum down and maybe try to get a little bit of a vaginal margin and the margin on the uterus saccals. Just really to make sure that you do have margins because typically if we get it right, survival outcomes of clinical stage 1 early cervix cancer 1B1 1B 2 are actually really good. It is a very important thing that we get the treatment right. In my practice, I use a software to record my treatment outcomes and my margins. And I would encourage all colleagues to be cognizant and to be responsible and accountable to introduce accountable clinical practice, to check on the margins and check on the number on the percentage of patients who require postoperative radiation treatment or chemo radiation. Dr. Ebony Hoskins: Very good. I have so many questions for you. I don't know the statistics in Australia, but here, there's increased rising of endometrial cancer and certainly we're seeing it in younger women. And fertility always comes up in terms of kind of what to do. And I look at the guidelines and, see if I can help some of the women if they have early-stage endometrial cancer. Your thoughts on what your practice is on use of someone who may meet criteria, if you will. The criteria I use is grade 1 endometrioid adenocarcinoma. No myometria invasion. I try to get MRI'd and make sure that there's no disease outside the endometrium. And then if they make criteria, I typically would do an IUD. Can you tell me what your practice is and where you've had success? Dr. Andreas Obermair: So, we initiated the feMMe clinical trial that was published in 2021 and it was presented in a Plenary at one of the SGO meetings. I think it was in 2021, and we've shown complete pathological response rates after levonorgestrel intrauterine device treatment. And so in brief, we enrolled patients with endometrial hyperplasia with atypia, but also patients with grade 1 endometrial adenocarcinoma. Patients with endometrial hyperplasia with atypia had, in our series, had an 85 % chance of developing a complete pathological response. And that was defined as the complete absence of any atypia or cancer. So endometrial hyperplasia with atypia responded in about 85%. In endometrial cancer, it was about half, it was about 45, 50%. In my clinical practice, like as you, I see patients, you know, five days a week. So I'm looking after many patients who are now five years down from conservative treatment of endometrial cancer. There are a lot of young women who want to get pregnant, and we had babies, and we celebrate the babies obviously because as gynecologist obstetricians it couldn't get better than that, right, if our cancer patients have babies afterwards. But we're also treating women who are really unfit for surgery and who are frail and where a laparoscopic hysterectomy would be unsafe. So this phase is concluded, and I think that was very successful. At least we're looking to validate our data. So we're having collaborations, we're having collaborations in the United States and outside the United States to validate these data. And the next phase is obviously to identify predictive factors, to identify predictors of response. Because as you can imagine, there is no point treating patients with a levonorgestrel intrauterine joint device where we know in advance that she's not going to respond. So this is a very, very fascinating story and we got our first set of data already, but now we just really need to validate this data. And then once the validation is done, my unit is keen to do a prospective validation trial. And that also needs to involve international collaborators. Dr. Ebony Hoskins: Very good. Moving on to ovarian cancer, we see patients with ovarian cancer with, say, at least stage 3C or higher who started neoadjuvant chemotherapy. Now, some of these patients are hearing different things from their medical oncologist versus their gynecologic oncologist regarding the number of cycles of neoadjuvant chemotherapy after getting diagnosed with ovarian cancer. I know that this can be confusing for our patients coming from a medical oncologist versus a gynecologic oncologist. What do you say to a patient who is asking about the ideal number of chemotherapy cycles prior to surgery? Dr. Andreas Obermair: So this is obviously a very, very important topic to talk about. We won't be able to provide a simple off the shelf answer for that, but I think data are emerging.  The ASCO guidelines should also be worthwhile considering because there are actually new ASCO Guidelines [on neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer] that just came out a few weeks ago and they would suggest that we should be aiming for R0 in surgery. If we can maybe take that as the pivot point and then go back and say, okay, so what do need to do to get the patient to zero?  I'm not an ovarian cancer researcher; I'm obviously a practicing gynecologic oncologist. I think about things a lot and things like that. In my practice, I would want a patient to develop a response after neoadjuvant chemotherapy. So, if a patient doesn't have a response after two or three cycles, then I don't see the point for me to offer her an operation. In my circle with the medical oncologists that I work with, I have a very, very good understanding. So, they send the patient to me, I take them to the theater. I take a good chunk of tissue from the peritoneum. We have a histopathologic diagnosis, we have a genomic diagnosis, they go home the same day. So obviously there is no hospital stay involved with that. They can start the chemotherapy after a few days. There is no hold up because the chances of surgical complication in a setting like this is very, very low. So I use laparoscopy to determine whether the patient responds or not. And for many of my patients, it seems to work. It's obviously a bit of an effort and it takes operating time. But I think I'm increasing my chances to make the right decision. So, coming back to your question about whether we should give three or six cycles, I think the current recommendations are three cycles pending the patient's response to neoadjuvant chemotherapy because my aim is to get a patient to R0 or at least minimal residual disease. Surgery is really, in this case, I think surgery is the adjunct to systemic treatment. Dr. Ebony Hoskins: Definitely. I think you make a great point, and I think the guideline just came out, like you mentioned, regarding neoadjuvant. And I think the biggest thing that we need to come across is the involvement of a gynecologic oncologist in patients with ovarian cancer. And we know that that survival increases with that involvement. And I think the involvement is the surgery, right? So, maybe we've gotten away from the primary tumor debulking and now using more neoadjuvant, but surgery is still needed. And so, I definitely want to have a take home that GYN oncology is involved in the care of these patients upfront. Dr. Andreas Obermair: I totally support that. This is a very important statement. So when I'm saying surgery is the adjunct to medical treatment, I don't mean that surgery is not important. Surgery is very important. And the timing is important. And that means that the surgeons and the med oncs need to be pulling on the same string. The med oncs just want to get the cytotoxic into the patients, but that's not the point, right? We want to get the cytotoxic into the patients at the right time because if we are working under this precision surgery, precision treatment mantra, it's not only important what we do, but also doing it at the right time. And ideally, I I would like to give surgery after three cycles of neoadjuvant chemotherapy, if that makes sense. But sometimes for me as a surgeon, I talk to my med onc colleagues and I say, “Look, she doesn't have a good enough response to her treatment and I want her to receive six cycles and then we re-evaluate or change medical treatment,” because that's an alternative that we can swap out drugs and treat upfront with a different drug and then sometimes they do respond. Dr. Ebony Hoskins:  I have maybe one more topic. In the area I'm in, in the Washington D.C. area, we see lots of endometrial cancer and they're not grade 1, right? They're high-risk endometrial cancer and advanced. So a number of patients with stage 3 disease, some just kind of based off staging and then some who come in with disease based off of the CT scan, sometimes omental caking, ascites. And the real question is we have extrapolated the use of neoadjuvant chemotherapy to endometrial cancer. It's similar, but not the same. So my question is in an advanced endometrial cancer, do you think there's still a role, when I say advanced, I mean, maybe stage 4, a role for surgery? Dr. Andreas Obermair: Most definitely. But the question is when do you want to give this surgery? Similar to ovarian cancer, in my experience, I want to get to R0. What am I trying to achieve here? So, I reckon we should do a trial on this. And I reckon we have, as you say, the number of patients in this setting is increasing, we could do a trial. I think if we collaborate, we would have enough patients to do a proper trial. Obviously, we would start maybe with a feasibility trial and things like that. But I reckon a trial would be needed in this setting because I find that the incidence that you described, that other people would come across, they're becoming more and more common. I totally agree with you, and we have very little data on that. Dr. Ebony Hoskins: Very little and we're doing what we can. Dr. Obermair, thank you for sharing your fantastic insights with us today on the ASCO Daily News Podcast and for all the work you do to advance care for patients with gynecologic cancer. Dr. Andreas Obermair: Thank you, Dr. Hoskins, for hosting this and it's been an absolute pleasure speaking with you today. Dr. Ebony Hoskins: Definitely a pleasure and thank you to our listeners for your time today. Again, Dr. Obermair's article is titled, “Controversies in the Surgical Management of Gynecologic Cancer: Balancing the Decision to Operate or Hesitate,” and was published in the 2024 ASCO Educational Book. And you'll find a link to the article in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Ebony Hoskins @drebonyhoskins Dr. Andreas Obermair @andreasobermair Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Ebony Hoskins: No relationships to disclose. Dr. Andreas Obermair: Leadership: SurgicalPerformance Pty Ltd. Stock and Ownership Interests: SurgicalPerformance Pty Ltd. Honoraria: Baxter Healthcare Consulting or Advisory Role: Stryker/Novadaq Patents, Royalties, and Other Intellectual Property: Shares in SurgicalPerformance Pty Ltd. Travel, Accommodation, Expenses: Stryker    

In this episode of the GOSH Podcast, host Sabine continues our rare cancer series with an esteemed guest, Dr. David Huntsman.

Robotic Surgery for Gynecologic Cancer: Transforming Patient Care with guest Dr. Elena Ratner March 2, 2025 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

In this episode of the GOSH Podcast, we kick off our rare cancer series with the inspiring Nancy McKinstry. In 2005, Nancy was diagnosed with clear cell ovarian cancer. Since then, she has embraced her “second life” by championing ovarian cancer research, helping secure $100 million in funding and creating initiatives like the Nancy McKinstry Trainee Excellence Award. Despite a recent recurrence, Nancy continues to make a lasting impact, growing an ovarian cancer research endowment now exceeding $934,000. Her story is one of resilience, generosity, and unwavering commitment to the future of women's health. Join us as we discuss her journey, the lessons she's learned, and the legacy she's building for generations to come. Resources:Donate to the Nancy McKinstry Endowment Fund for Ovarian Cancer at https://donate.bccancerfoundation.com/site/TR?px=2927503&fr_id=4394&pg=personal&s_src=LNY20 For more information on the Gynecologic Cancer Initiative, please visit https://gynecancerinitiative.ca/ or email us at info@gynecancerinitiative.ca Where to learn more about us: Twitter – @GCI_Cluster Instagram – @gynecancerinitiative Facebook – facebook.com/gynecancerinitiativeTikTok – @gci_gosh

On this episode of the GOSH Podcast, we are joined by Golda Arthur, award-winning host of the Overlooked podcast, and her mum Teresa Arthur, whose ovarian cancer journey inspired it all. After Teresa's diagnosis, the audio diaries she recorded became the foundation for Overlooked, a powerful podcast spotlighting women's health issues. Golda's 20-year career as a journalist has taken her from working at CBC and BBC to creating acclaimed shows like Land of the Giants, Today, Explained, and Overlooked. Meanwhile, Teresa has become an advocate in the cancer research community, combining her love of science with her experience as a survivor. Tune in as we explore Teresa's courageous story and Golda's mission to amplify women's voices through storytelling.

In this episode, Alexa Basilio, PharmD, BCOP and Jessica Davis, PharmD, BCOP, CPP discuss immune-related adverse events and toxicities among patients using immune checkpoint inhibitors. This overview will include discussion about: How and when to monitor and treat mild vs severe immune-related toxicitiesThe art of balancing and tapering low-dose and high-dose corticosteroidsDifferentiating between immune-related and chemotherapy- or targeted therapy–associated adverse events for optimal management approachesInvolvement of multidisciplinary teams early during treatment to prevent immune-related adverse eventsImportance of educating patients, caregivers, and providers on immune-related toxicitiesPresenters: Alexa Basilio, PharmD, BCOPUniversity of Florida College of Pharmacy Oncology Pharmacy Specialist McKesson, The US Oncology NetworkTampa, Florida Jessica Davis, PharmD, BCOP, CPP Levine Cancer InstituteClinical Pharmacist Coordinator, Adult Hematology/OncologyAtrium Health Levine CenterCharlotte, North Carolina Link to full program: https://bit.ly/3We4HJy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

Featuring perspectives from Dr Kathleen N Moore, moderated by Dr Stephen “Fred” Divers CME information and select publications

Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers.

Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Susana M. Campos, MD, MPH, about the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with HER2-positive gynecologic cancers. Dr Campos is the clinical director and the director of Educational Initiatives in the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Campos discussed the clinical implications of findings from the gynecologic cancer cohorts of the phase 2 DESTINY-PanTumor02 trial (NCT04482309).

Drs. Dietrich and Holloway continue sharing their insights into the pivotal role of HER2 positivity in gynecologic cancers. They discuss how HER2, a well-known biomarker in breast cancer, is increasingly recognized for its significance in other gynecologic malignancies, including ovarian and endometrial cancers.

Drs. Dietrich and Holloway share their insights into the pivotal role of HER2 positivity in gynecologic cancers. They discuss how HER2, a well-known biomarker in breast cancer, is increasingly recognized for its significance in other gynecologic malignancies, including ovarian and endometrial cancers.

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced Ovarian CancerATHENA COMBO/GOG-3020/ENGOT-ov45: Rucaparib With or Without Nivolumab Maintenance in Newly Diagnosed Ovarian CancerPhase II PICCOLO Trial of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer With High-FRα ExpressionPhase III KEYNOTE-B21/GOG-3053 Study of Adjuvant Chemotherapy With or Without Radiotherapy With or Without Pembrolizumab in Patients With Newly Diagnosed Endometrial Cancer or Carcinosarcoma After Curative Surgery With no Residual DiseasePhase III KEYNOTE-A18 Overall Survival Results: Pembrolizumab Plus Concurrent Chemoradiation in High-Risk Locally Advanced Cervical Cancer Program faculty:Ana Oaknin, MD, PhDHead of Gynaecologic Cancer ProgrammeDepartment of Medical OncologyVall d' Hebron University HospitalVall d'Hebron Institute of Oncology Barcelona, SpainAlexandra Leary, MD, PhDCo-Director, Department of Medical OncologyMedical Oncologist, GynecologyTeam Leader, Gynecologic Translational Research Lab, Institut Gustave RoussyParis, FranceResources:To download the slides associated with this podcast discussion, please visit the program page.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-evaluating-her2-directed-therapies-in-gynecologic-cancers/26792/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/diversity-in-her2-expression-among-gynecologic-cancers/26790/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

Dr Angeles Alvarez Secord from the Duke Cancer Institute in Durham, North Carolina, provides her perspectives on recent datasets from ASCO 2024 on the management of ovarian and endometrial cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayASCOOvarianEndo24).

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancerRUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancerSurvival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancerDUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancerLong-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatinSubgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator's choice of chemotherapy in FR

Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists Editorial: Who you gonna call? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring:M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter HealthConnor C. Wang, MD, Northwestern University Feinberg School of MedicineEmma Barber, MD, MS, Northwestern University Feinberg School of Medicine

Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists Editorial: Who you gonna call? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring:M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter HealthConnor C. Wang, MD, Northwestern University Feinberg School of MedicineEmma Barber, MD, MS, Northwestern University Feinberg School of Medicine

Featuring perspectives from Dr Bradley J Monk and Dr David M O'Malley, including the following topics. Introduction (0:00) Ovarian Cancer; Role of HER2-Directed Therapy in Gynecologic Cancers — Dr O'Malley (4:36) Endometrial Cancer and Cervical Cancer — Dr Monk (27:59) CME information and select publications

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

Featuring an interview with Dr David M O'Malley, including the following topics: Prevalence of HER2 positivity among various gynecologic cancer subtypes; current testing recommendations (0:00) Trastuzumab and other HER2-targeted therapies as a component of treatment for HER2-positive gynecologic cancers (15:17) Key efficacy outcomes achieved with trastuzumab deruxtecan (T-DXd) among patients with advanced ovarian, endometrial and cervical cancers in the DESTINY-PanTumor02 study (18:05) Incidence of interstitial lung disease (ILD) and other toxicities with T-DXd in the DESTINY-PanTumor02 trial; strategies to manage ILD associated with HER2-directed antibody-drug conjugates (27:59) Case: A woman in her mid-60s with HER2-low (IHC 1+) recurrent uterine carcinosarcoma receives T-DXd on a clinical trial (34:26) Case: A woman in her mid-70s with recurrent uterine serous cancer and history of Crohn's disease (51:05) Case: A woman in her mid-60s with Stage IIIC primary uterine serous cancer receives carboplatin/paclitaxel/trastuzumab followed by maintenance trastuzumab with no evidence of disease 4 years later (56:50) CME information and select publications

Dr David M O'Malley from The Ohio State University and the James Comprehensive Cancer Center in Columbus, Ohio discusses the role of HER2-directed therapy in the treatment of gynecologic cancers. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/1Gyn).

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BVX865. CME/MOC/AAPA/IPCE credit will be available until December 10, 2024.The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Eisai Inc., and Seagen and Genmab.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Acrivon Therapeutics; Adaptimmune Therapeutics plc.; Agenus Inc.; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; AstraZeneca; Bayer Corporation; Clovis Oncology; Eisai Inc.; Elevar, LLC; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Genmab A/S/Seagen Inc.; The GOG Foundation Inc; Gradalis, Inc.; ImmunoGen, Inc.; Iovance Biotherapeutics, Inc.; Jiangsu Hengrui Pharmaceuticals Co., Ltd.; Karyopharm; Laekna Therapeutics; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure GmbH; OncoC4, Inc.; Panavance Therapeutics Inc.; Pfizer; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; Sorrento Therapeutics, Inc.; TESARO, Inc./GlaxoSmithKline; US Oncology Research, LLC; VBL Therapeutics; Verastem, Inc.; and Zentalis Pharmaceuticals.Grant/Research Support from US Oncology Research, LLC.Speaker for AstraZeneca; Clovis Oncology; Eisai Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Merck & Co., Inc.; and TESARO, Inc./GlaxoSmithKline.Faculty/PlannerAna Oaknin, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera Pharmaceuticals; Eisai Co., Ltd.; EMD Serono; Exelisis, Inc.; F. Hoffmann-La Roche; Genmab A/S; GlaxoSmithKline; ImmunoGen, Inc.; iTeos Therapeutics; Merck Sharp & Dohme de Espana SA; Mersana Therapeutics; Novocure GmbH; OncXerna Therapeutics, Inc.; Pharma Mar SA; Regeneron Pharmaceuticals Inc.; Seagen, Inc.; Shattuck Labs, Inc.; and Sutro Biopharma, Inc.Grant/Research Support from AbbVie Deutschland; Advaxis Inc.; Aeterna Zentaris; Amgen Inc.; Aprea Therapeutics AB; Bristol Myers Squibb; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche; ImmunoGen, Inc.; Merck Sharp & Dohme de Espana SA; Millennium Pharmaceuticals Inc.; Pharma Mar SA; Regeneron Pharmaceuticals Inc; and Tesaro.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Featuring perspectives from Dr Richard T Penson and Dr Krishnansu S Tewari, including the following topics: Introduction: Pan-tumor Indications for New Therapies (0:00) Endometrial Cancer (14:13) Treatment of Cervical Cancer (32:38) Updates in Ovarian Cancer (45:41) CME information and select publications

Dr Richard Penson from Massachusetts General Hospital in Boston, Massachusetts and Dr Krishnansu Tewari from the University of California, Irvine, discuss updated data from the 2023 ESMO Congress on optimal management approaches for gynecologic cancers. CME information and select publications here (https://www.researchtopractice.com/PostESMO23/Gyn).

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Ovarian Cancer — Kathleen N Moore, MD, MS (4:14) Endometrial and Cervical Cancers — Bradley J Monk, MD (41:09) CME information and select publications